Biotex Natto+: A Polyherbal Nutraceutical Targeted For Cardiovascular Health.
DOI:
https://doi.org/10.22270/ajprd.v14i4.1855Abstract
Objective(s): To assess clinical, preclinical, regulatory and safety evidence on the efficacy of nattokinase in cardiovascular health and the rationale for the combination formulation of Biotex Natto+ (nattokinase 250 mg, bromelain 250 mg, standardised nanocurcumin 50 mg).
Data Sources: Relevant published studies were retrieved from PubMed, Scopus and Google Scholar.
Study Selection: Published clinical trials, systematic reviews, meta-analyses and preclinical studies with methodological rigour investigating the effect of nattokinase and/or combination therapy on blood pressure, fibrinolytic activity, haemostatic factors, atherosclerosis and carotid intima-media thickness were selected.
Summary of Contents: Cardiovascular diseases are the leading cause of death worldwide despite the availability of effective pharmacological interventions. Nattokinase is a 27.7 kDa subtilisin-like serine protease from natto that has been extensively investigated as a fibrinolytic nutraceutical. Clinical studies provide preliminary evidence on the antihypertensive, fibrinolytic, anti-inflammatory and anti-atherosclerotic effects of nattokinase. Moderate decreases in systolic and diastolic blood pressures and plasma fibrinogen, coagulation factors VII and VIII were reported alongside improvement in carotid intima-media thickness. Bromelain and curcumin nanoparticles may contribute additional cardioprotective effects, although evidence on the formulated product is indirect.
Conclusion: Nattokinase possesses cardioprotective properties and further clinical studies are warranted to establish the efficacy of the formulated product, Biotex Natto+.
Downloads
References
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010
Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese natto: a typical and popular soybean food in the Japanese diet. Experientia. 1987;43(10):1110-1111. doi:10.1007/BF01956052
Fujita M, Nomura K, Hong K, Ito Y, Asada A, Nishimuro S. Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem Biophys Res Commun. 1993;197(3):1340-1347. doi:10.1006/bbrc.1993.2624
Kim JY, Gum SN, Paik JK, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res. 2008;31(8):1583-1588. doi:10.1291/hypres.31.1583
Hsia CH, Shen MC, Lin JS, et al. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res. 2009;29(3):190-196. doi:10.1016/j.nutres.2009.01.009
Li X, Long J, Gao Q, et al. Nattokinase supplementation and cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Rev Cardiovasc Med. 2023;24(8):234. doi:10.31083/j.rcm2408234
Altaf F, Wu S, Kasim V. Role of fibrinolytic enzymes in anti-thrombosis therapy. Front Mol Biosci. 2021;8:680397. doi:10.3389/fmolb.2021.680397
Granito M, Alvarenga L, Ribeiro M, Lima V, Cardozo LFMF, Mafra D. Nattokinase as an adjuvant therapeutic strategy for non-communicable diseases: a review of fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant effects. Expert Rev Cardiovasc Ther. 2024;22(10):565-574. doi:10.1080/14779072.2024.2416663
Chen H, McGowan EM, Ren N, et al. Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomark Insights. 2018;13:1177271918785130. doi:10.1177/1177271918785130
Biotex Life Solutions. Biotex Natto+: product information. Accessed May 26, 2026. https://shop.biotexlife.com/products/natto
Food Safety and Standards Authority of India. Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2022. Accessed May 26, 2026. https://fssai.gov.in
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Safety of fermented soybean extract NSK-SD as a novel food pursuant to Regulation (EC) No 258/97. EFSA J. 2016;14(9):4541. doi:10.2903/j.efsa.2016.4541
Nakamura T, Yamagata Y, Ichishima E. Nucleotide sequence of the subtilisin NAT gene, aprN, of Bacillus subtilis (natto). Biosci Biotechnol Biochem. 1992;56(11):1869-1871. doi:10.1271/bbb.56.1869
Pan X, Liang P, Teng L, et al. Study on molecular mechanisms of nattokinase in pharmacological action based on label-free liquid chromatography-tandem mass spectrometry. Food Sci Nutr. 2019;7(10):3185-3193. doi:10.1002/fsn3.1157
Sheng Y, Yang J, Wang C, Sun X, Yan L. Microbial nattokinase: from synthesis to potential application. Food Funct. 2023;14(6):2568-2585. doi:10.1039/d2fo03389e
Shah S, Patel J, Patel R. Nattokinase: armour against thrombosis. J Adv Sci Res. 2022;13(5):27-32. doi:10.55218/jasr.202213504
Fujita M, Hong K, Ito Y, et al. Transport of nattokinase across the rat intestinal tract. Biol Pharm Bull. 1995;18(9):1194-1196. doi:10.1248/bpb.18.1194
Guo H, Ban YH, Cha Y, et al. Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator. Food Sci Biotechnol. 2019;28(5):1535-1542. doi:10.1007/s10068-019-00580-1
Urano T, Ihara H, Umemura K, et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem. 2001;276(27):24690-24696. doi:10.1074/jbc.M101751200
Yatagai C, Maruyama M, Kawahara T, Sumi H. Nattokinase-promoted tissue plasminogen activator release from human cells. Pathophysiol Haemost Thromb. 2009;36(5):227-232. doi:10.1159/000252817
Ji H, Yu L, Liu K, et al. Mechanisms of nattokinase in protection of cerebral ischemia. Eur J Pharmacol. 2014;745:144-151. doi:10.1016/j.ejphar.2014.10.024
Kurosawa Y, Nirengi S, Homma T, et al. A single dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep. 2015;5:11601. doi:10.1038/srep11601
Jang JY, Kim TS, Cai J, et al. Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation. Lab Anim Res. 2013;29(4):221-225. doi:10.5625/lar.2013.29.4.221
Zhang L, Jia S, Platt MO, Xu Y. Interactions between nattokinase and heparin/GAGs. Glycoconj J. 2015;32(9):695-702. doi:10.1007/s10719-015-9620-8
Fujita M, Ohnishi K, Takaoka S, Ogasawara K, Fukuyama R, Nakamuta H. Antihypertensive effects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(11):1696-1701. doi:10.1248/bpb.34.1696
Murakami K, Yamanaka N, Ohnishi K, Fukayama M, Yoshino M. Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. Food Funct. 2012;3(6):674-678. doi:10.1039/c2fo10245e
Feng H, Liu C, Liu Q, et al. Study on the transport and internalisation mechanism of dietary supplement nattokinase in the small intestine using animal and Caco-2 cell monolayer models. Xenobiotica. 2023;53(12):670-680. doi:10.1080/00498254.2023.2284249
Ero MP, Ng CM, Mihailovski T, Harvey NR, Lewis BH. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Altern Ther Health Med. 2013;19(3):16-19.
Cai D, Zhu C, Chen S. Microbial production of nattokinase: current progress, challenge and prospect. World J Microbiol Biotechnol. 2017;33(5):84. doi:10.1007/s11274-017-2253-2
Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001;58(9):1234-1245. doi:10.1007/PL00000936
Pavan R, Jain S, Shraddha, Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203. doi:10.1155/2012/976203
Chobotova K, Vernallis AB, Majid FAA. Bromelain’s activity and potential as an anti-cancer agent: current evidence and perspectives. Cancer Lett. 2010;290(2):148-156. doi:10.1016/j.canlet.2009.08.001
Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92. doi:10.3390/foods6100092
Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol. 2009;133(2):145-151. doi:10.1016/j.ijcard.2009.01.073
Mayanglambam A, Dangelmaier CA, Thomas D, Damodar Reddy C, Daniel JL, Kunapuli SP. Curcumin inhibits GPVI-mediated platelet activation by interfering with the kinase activity of Syk and the subsequent activation of PLCγ2. Platelets. 2010;21(3):211-220. doi:10.3109/09537100903528269
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807-818. doi:10.1021/mp700113r
Flory S, Sus N, Haas K, et al. Increasing post-digestive solubility of curcumin is the most successful strategy to improve its oral bioavailability: a randomized cross-over trial in healthy adults and in vitro bioaccessibility experiments. Mol Nutr Food Res. 2021;65(24):e2100613. doi:10.1002/mnfr.202100613
Yang NC, Chou CW, Chen CY, Hwang KL, Yang YC. Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia. Asia Pac J Clin Nutr. 2009;18(3):310-317.
Liu X, Zeng X, Mahe J, et al. The effect of nattokinase-Monascus supplements on dyslipidemia: a four-month randomized, double-blind, placebo-controlled clinical trial. Nutrients. 2023;15(19):4239. doi:10.3390/nu15194239
Jensen GS, Lenninger M, Ero MP, Benson KF. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. 2016;9:95-104. doi:10.2147/IBPC.S99553
Hitosugi M, Hamada K, Misaka K. Effects of Bacillus natto products on blood pressure in patients with lifestyle diseases. J Hypertens Open Access. 2013;4(3):135. doi:10.4172/2167-1095.1000135
Yoo HJ, Kim M, Kim M, et al. The effects of nattokinase supplementation on collagen-epinephrine closure time, prothrombin time and activated partial thromboplastin time in nondiabetic and hypercholesterolemic subjects. Food Funct. 2019;10(5):2888-2893. doi:10.1039/c8fo02324g
Ren NN, Chen HJ, Li Y, McGowan GW, Lin YG. A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Zhonghua Yi Xue Za Zhi. 2017;97(26):2038-2042. doi:10.3760/cma.j.issn.0376-2491.2017.26.005
Chen H, Chen J, Zhang F, et al. Effective management of atherosclerosis progression and hyperlipidemia with nattokinase: a clinical study with 1,062 participants. Front Cardiovasc Med. 2022;9:964977. doi:10.3389/fcvm.2022.964977
Hodis HN, Mack WJ, Meiselman HJ, et al. Nattokinase atherothrombotic prevention study: a randomized controlled trial. Clin Hemorheol Microcirc. 2021;78(4):339-353. doi:10.3233/CH-211147
Wei C, Cai R, Song Y, Liu X, Xu HL. Research progress of nattokinase in reducing blood lipid. Nutrients. 2025;17(11):1784. doi:10.3390/nu17111784
Pham PT, Han B, Hoang BX. Nattospes as effective and safe functional supplements in management of stroke. J Med Food. 2020;23(8):879-885. doi:10.1089/jmf.2019.0183
Cesarone MR, Belcaro G, Nicolaides AN, et al. Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized, controlled trial. Angiology. 2003;54(5):531-539. doi:10.1177/000331970305400502
Yang XY, Wang SL, Xue WC, et al. Nattokinase’s neuroprotective mechanisms in ischemic stroke: targeting inflammation, oxidative stress, and coagulation. Antioxid Redox Signal. 2024;42(4-6):228-248. doi:10.1089/ars.2023.0527
Mahakalakar N, Mohariya G, Taksande B, Kotagale N, Umekar M, Vinchurney M. Nattokinase as a potential therapeutic agent for preventing blood-brain barrier dysfunction in neurodegenerative disorders. Brain Res. 2024;1849:149352. doi:10.1016/j.brainres.2024.149352
Gallelli G, Di Mizio G, Palleria C, et al. Data recorded in real life support the safety of nattokinase in patients with vascular diseases. Nutrients. 2021;13(6):2031. doi:10.3390/nu13062031
Lampe BJ, English JC. Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food Chem Toxicol. 2016;88:87-99. doi:10.1016/j.fct.2016.01.001
Memorial Sloan Kettering Cancer Center. Nattokinase: about herbs. Accessed May 26, 2026. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/nattokinase
Chang YY, Liu JS, Lai SL, Wu HS, Lan MY. Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. Intern Med. 2008;47(5):467-469. doi:10.2169/internalmedicine.47.0620
Dobre MZ, Virgolici B, Doicin IC, Vîrgolici H, Stanescu-Spinu II. Navigating the effects of anti-atherosclerotic supplements and acknowledging associated bleeding risks. Int J Mol Sci. 2025;26(20):10183. doi:10.3390/ijms262010183
Muric M, Nikolic M, Todorovic A, Jakovljevic V, Vucicevic K. Comparative cardioprotective effectiveness: NOACs vs nattokinase-bridging basic research to clinical findings. Biomolecules. 2024;14(8):956. doi:10.3390/biom14080956
Afzaal M, Saeed F, Islam F, et al. Nutritional health perspective of natto: a critical review. Biochem Res Int. 2022;2022:5863887. doi:10.1155/2022/5863887
Published
How to Cite
Issue
Section
Copyright (c) 2026 Pratiksha Tekale, Sneha Chatur ; Dnyaneshwari Jadhav , Aishwarya Erande; Rasika Bhalke , Mahendra Giri
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 